The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 1,022
Guichet, P., Guelfi, S., Teigell, M., Hoppe, L., Bakalara, N., Bauchet, L., Duffau, H., Lamszus, K., Rothhut, B., & Hugnot, J. (2014) · Stem Cells · doi:10.1002/stem.1767 · Cited by 140
Oncogenic extracellular vesicles in brain tumor progression
D’Asti, E., Garnier, D., Lee, T. H., Montermini, L., Meehan, B., & Rak, J. W. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00294 · Cited by 134
Invasion as target for therapy of glioblastoma multiforme
Vehlow, A., & Cordes, N. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.07.001 · Cited by 137
Yao, J., Caballero, O. L., Yung, W. K. A., Weinstein, J. N., Riggins, G. J., Strausberg, R. L., & Zhao, Q. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0088 · Cited by 129
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 131
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis
Hoeman, C. M., Cordero, F. J., Hu, G., Misuraca, K., Romero, M. M., Cardona, H. J., Nazarian, J., Hashizume, R., McLendon, R. E., Yu, P. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08823-9 · Cited by 133
Sreekanthreddy, P., Srinivasan, H., Kumar, D. M., Nijaguna, M. B., Sridevi, S., Marigowda, V., Arivazhagan, A., Balasubramaniam, A., Hegde, A. S., Chandramouli, B. A., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-1077 · Cited by 132
Chow, K.-H., Park, H. J., George, J., Yamamoto, K., Gallup, A. D., Graber, J. H., Chen, Y., Jiang, W., Steindler, D. A., Neilson, E. G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1294 · Cited by 135
An Experimenter’s Guide to Glioblastoma Invasion Pathways
de Gooijer, M. C., Navarro, M. G., Bernards, R., Würdinger, T., & van Tellingen, O. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.07.003 · Cited by 129
An update on the central nervous system manifestations of neurofibromatosis type 1
Nix, J. S., Blakeley, J. O., & Rodríguez, F. J. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02002-2 · Cited by 128
Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer
Hassan, N., Greve, B., Espinoza‐Sánchez, N. A., & Götte, M. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109822 · Cited by 129
Creighton, C. J., Hernández-Herrera, A., Jacobsen, A., Levine, D. A., Mankoo, P. K., Schultz, N. D., Du, Y., Zhang, Y., Larsson, E., Sheridan, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034546 · Cited by 127
Self-citationGalvão, R. P., Kasina, A., McNeill, R. S., Harbin, J. E., Foreman, O., Verhaak, R. G. W., Nishiyama, A., Miller, C. R., & Zong, H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414389111 · Cited by 136
Self-citationMallawaaratchy, D. M., Hallal, S. M., Russell, B., Ly, L., Ebrahimkhani, S., Wei, H., Christopherson, R. I., Buckland, M. E., & Alexander, K. L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2298-3 · Cited by 132
Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
Li, G., Wang, Z., Zhang, C., Liu, X., Cai, J., Wang, Z., Hu, H., Wu, F., Bao, Z., Liu, Y., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328339 · Cited by 126
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
Saenz‐Antoñanzas, A., Auzmendi-Iriarte, J., Carrasco‐García, E., Moreno‐Cugnon, L., Ruiz, I., Villanúa, J., Egaña, L., Otaegui, D., Samprón, N., & Matheu, A. (2019) · Cancers · doi:10.3390/cancers11070950 · Cited by 129
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
Lan, Z., Li, X., & Zhang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053040 · Cited by 127
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L. E., Villanueva-Meyer, J. E., Winkler, E. A., & de Groot, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01338-x · Cited by 140
Cimino, P. J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0443-7 · Cited by 126
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Jhanwar‐Uniyal, M., LaBagnara, M., Friedman, M., Kwasnicki, A. M., & Murali, R. (2015) · Cancers · doi:10.3390/cancers7020538 · Cited by 130
Little, S. E., Popov, S., Jury, A., Bax, D. A., Doey, L. J., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4069 · Cited by 123
Xie, Q. R., Bradley, R., Kang, L., Koeman, J. M., Ascierto, M. L., Worschech, A., Giorgi, V. D., Wang, E., Kefene, L., Su, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119059109 · Cited by 128
Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007
Dubrow, R., & Darefsky, A. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-325 · Cited by 127
Characterization of gliomas: from morphology to molecules
Ferris, S. P., Hofmann, J. W., Solomon, D. A., & Perry, A. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2181-4 · Cited by 130
The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes
Huang, K., Fang, C., Yi, K., Liu, X., Qi, H., Tan, Y., Zhou, J., Li, Y., Liu, M., Zhang, Y., et al. (2018) · Theranostics · doi:10.7150/thno.22952 · Cited by 126
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors
Lauko, A. J., Lo, A., Ahluwalia, M. S., & Lathia, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.014 · Cited by 132
Yan, X. S., Ma, L., Yi, D., Yoon, J.-G., Diercks, A. H., Foltz, G., Price, N. D., Hood, L., & Tian, Q. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018696108 · Cited by 130
Silber, J., Skanderup, A. J., Ozawa, T., Harinath, G., Pedraza, A. M., Sander, C., Holland, E. C., & Huse, J. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033844 · Cited by 130
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130
Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye‐Agyeman, F., Bakken, K. K., Pokorny, J. L., Schroeder, M. A., Decker, P. A., Cen, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv369 · Cited by 128
Self-citationRasmussen, R. D., Gajjar, M. K., Tučková, L., Jensen, K. E., Maya‐Mendoza, A., Holst, C. B., Møllgaard, K., Rasmussen, J. S., Brennum, J., Bartek, J. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13398 · Cited by 125
Uribe, D., Torres, Á., Rocha, J. D., Niechi, I., Oyarzun, C. E., Sobrevía, L., Martín, R. S., & Quezada, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.009 · Cited by 127
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
Immunotherapies for malignant glioma
Boussiotis, V. A., & Charest, A. (2017) · Oncogene · doi:10.1038/s41388-017-0024-z · Cited by 126
Experimental models and tools to tackle glioblastoma
Robertson, F., Marqués‐Torrejón, M. Á., Morrison, G. M., & Pollard, S. M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040386 · Cited by 127
An integrative analysis of the age-associated multi-omic landscape across cancers
Chatsirisupachai, K., Lesluyes, T., Paraoan, L., Loo, P. V., & de Magalhães, J. P. (2021) · Nature Communications · doi:10.1038/s41467-021-22560-y · Cited by 128
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma
Buczkowicz, P., & Hawkins, C. E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00147 · Cited by 128
Deregulation of cell signaling in cancer
Giancotti, F. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.005 · Cited by 133
Alternative transcription and alternative splicing in cancer
Pal, S., Gupta, R., & Davuluri, R. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.005 · Cited by 128
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments
Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., Schopow, K., Hellwig, C. T., Schäfer, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not003 · Cited by 123
Opposing roles of connexin43 in glioma progression
Sin, W., Crespin, S., & Mesnil, M. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.10.022 · Cited by 124
Fajardo, N. M. P., Meijer, C., & Kruyt, F. A. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.008 · Cited by 122
Management of glioblastoma after recurrence: A changing paradigm
Mallick, S., Benson, R., Hakim, A., & Rath, G. K. (2016) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2016.07.001 · Cited by 124
EMT Regulation by Autophagy: A New Perspective in Glioblastoma Biology
Colella, B., Faienza, F., & Bartolomeo, S. D. (2019) · Cancers · doi:10.3390/cancers11030312 · Cited by 128
Mueller, S., Jain, P., Liang, W. S., Kilburn, L. B., Kline, C., Gupta, N. M., Panditharatna, E., Magge, S. N., Zhang, B., Zhu, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32258 · Cited by 120
Yang, R. R., Shi, Z., Zhang, Z., Chan, A. K., Aibaidula, A., Wang, W., Kwan, J. S. H., Poon, W. S., Chen, H., Li, W., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12801 · Cited by 122
Glioblastoma hijacks microglial gene expression to support tumor growth
Maas, S. L. N., Abels, E. R., van de Haar, L. L., Zhang, X., Morsett, L. M., Sil, S., Guedes, J. R., Sen, P., Prabhakar, S., Hickman, S. E., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01797-2 · Cited by 128
Chen, A., Gartrell, R. D., Zhao, J., Upadhyayula, P. S., Zhao, W., Yuan, J., Minns, H. E., Dovas, A., Bruce, J. N., Lasorella, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00906-x · Cited by 125
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126
Xu, J., Wu, P., Chen, Y., Meng, Q., Dawood, H., & Dawood, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3116-7 · Cited by 123
A prognostic neural epigenetic signature in high-grade glioma
Drexler, R., Khatri, R., Sauvigny, T., Mohme, M., Maire, C. L., Ryba, A. S., Zghaibeh, Y., Dührsen, L., Salviano‐Silva, A., Lamszus, K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02969-w · Cited by 141
Pollack, I. F. (2011) · Journal of Neurosurgery Pediatrics · doi:10.3171/2011.5.peds1178 · Cited by 120
Alterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 124
DeLay, M., Jahangiri, A., Carbonell, W. S., Hu, Y., Tsao, S. W., Tom, M. W., Paquette, J., Tokuyasu, T. A., & Aghi, M. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2390 · Cited by 118
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Laffaire, J., Everhard, S., Idbaïh, A., Crinière, E., Marie, Y., de Reyniès, A., Schiappa, R., Mokhtari, K., Hoang‐Xuan, K., Sanson, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq110 · Cited by 121
Nikiforova, M. N., Wald, A. I., Melan, M. A., Roy, S., Zhong, S., Hamilton, R. L., Lieberman, F. S., Drappatz, J., Amankulor, N., Pollack, I. F., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov289 · Cited by 121
Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
Garros-Regulez, L., García, I., Carrasco‐García, E., Lantero, A., Aldaz, P., Moreno‐Cugnon, L., Arrizabalaga, O., Undabeitia, J. I., Torres-Bayona, S., Villanúa, J., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00222 · Cited by 130
Yu, D., Khan, O. F., Suvà, M. L., Dong, B., Panek, W. K., Xiao, T., Wu, M., Han, Y., Ahmed, A. U., Balyasnikova, I. V., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701911114 · Cited by 123
Breaking through the glioblastoma micro-environment via extracellular vesicles
Simon, T., Jackson, E., & Giamas, G. (2020) · Oncogene · doi:10.1038/s41388-020-1308-2 · Cited by 123
Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies
Hamad, A., Yusubalieva, G. M., Baklaushev, V. P., Chumakov, P. M., & Lipatova, A. V. (2023) · Viruses · doi:10.3390/v15020547 · Cited by 124
DINGO: differential network analysis in genomics
Ha, M. J., Baladandayuthapani, V., & Do, K.-A. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv406 · Cited by 120
Proteogenomic Database Construction Driven from Large Scale RNA-seq Data
Woo, S., Cha, S. W., Merrihew, G. E., He, Y., Castellana, N. E., Guest, C. C., MacCoss, M. J., & Bafna, V. (2013) · Journal of Proteome Research · doi:10.1021/pr400294c · Cited by 121
Lu, F., Chen, Y., Zhao, C., Wang, H., He, D., Xu, L., Wang, J., He, X., Deng, Y., Lu, E. E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.027 · Cited by 123
CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone
Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Valentin, E. D., Berendsen, S., Dedobbeleer, M., Willems, E., Robe, P. A. J. T., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now136 · Cited by 120
Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation
Choi, D., Lee, T. H., Spinelli, C., Chennakrishnaiah, S., D’Asti, E., & Rak, J. W. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.003 · Cited by 121
NF-κB Signalling in Glioblastoma
Soubannier, V., & Stifani, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020029 · Cited by 123
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model
Haag, D., Mack, N. L., da Silva, P. B. G., Statz, B., Clark, J., Tanabe, K., Sharma, T., Jäger, N., Jones, D., Kawauchi, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.005 · Cited by 127
Translating cancer ‘omics’ to improved outcomes: Figure 1.Preprint
Vucic, E. A., Thu, K. L., Robison, K. E., Rybaczyk, L. A., Chari, R., Alvarez, C. E., & Lam, W. L. (2012) · Genome Research · doi:10.1101/gr.124354.111 · Cited by 124
Uchida, H., Marzulli, M., Nakano, K., Goins, W. F., Chan, J., Hong, C., Mazzacurati, L., Yoo, J. Y., Haseley, A., Nakashima, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.211 · Cited by 119
Chen, L., Han, L., Zhang, K., Shi, Z., Zhang, J., Zhang, A., Wang, Y., Song, Y., Li, Y., Jiang, T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos122 · Cited by 118
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yan, J., Zhao, Q., Gabrusiewicz, K. R., Kong, L.-Y., Xia, X., Wang, J., Ott, M., Xu, J., Davis, R. E., Huo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08271-x · Cited by 117
Bhaskaran, V., Nowicki, M. O., Idriss, M., Jimenez, M. A., Lugli, G., Hayes, J. L., Mahmoud, A. B., Zane, R. E., Passaro, C., Ligon, K. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08390-z · Cited by 105
Geraldo, L. H., Xu, Y., Jacob, L., Pibouin-Fragner, L., Rao, R., Maïssa, N., Verreault, M., Lemaire, N., Knosp, C. A., Lesaffre, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141083 · Cited by 119
Yang, B., Zhong, C., Peng, Y., Lai, Z., & Ding, J. (2010) · Cell Research · doi:10.1038/cr.2010.145 · Cited by 121
Appin, C., & Brat, D. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000020 · Cited by 122
Annexin A2 Promotes Glioma Cell Invasion and Tumor Progression
Zhai, H., Acharya, S. S., Gravanis, I., Mehmood, S., Seidman, R., Shroyer, K. R., Hajjar, K. A., & Tsirka, S. E. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3299-11.2011 · Cited by 121
Schulte, A., Günther, H. S., PHILLIPS, H. S., Kemming, D., Martens, T., Kharbanda, S., Soriano, R. H., Modrusan, Z. D., Zapf, S., Westphal, M., et al. (2011) · Glia · doi:10.1002/glia.21127 · Cited by 118
Newly Diagnosed Glioblastoma: A Review on Clinical Management.
Lukas, R. V., Wainwright, D. A., Ladomersky, E., Sachdev, S., Sonabend, A. M., & Stupp, R. (2019) · PubMed · Cited by 122
Ding, H., Douglass, E. F., Sonabend, A. M., Mela, A., Bose, S., Gonzalez, C., Canoll, P., Sims, P. A., Alvarez, M. J., & Califano, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03843-3 · Cited by 116
Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
Miow, Q. H., Tan, T. Z., Ye, J., Lau, J. A., Yokomizo, T., Thiery, J.-P., & Mori, S. (2015) · Oncogene · doi:10.1038/onc.2014.136 · Cited by 117
Imaging descriptors improve the predictive power of survival models for glioblastoma patients
Mazurowski, M. A., Desjardins, A., & Malof, J. M. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos335 · Cited by 114
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy
Yi, Y., Hsieh, I.-Y., Huang, X., Li, J., & Zhao, W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00477 · Cited by 105
Drug Repositioning in Glioblastoma: A Pathway Perspective
Tan, S. K., Jermakowicz, A. M., Mookhtiar, A. K., Nemeroff, C. B., Schürer, S. C., & Ayad, N. G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00218 · Cited by 116
Ribosome Profiling Reveals a Cell-Type-Specific Translational Landscape in Brain Tumors
Gonzalez, C., Sims, J. S., Hornstein, N., Mela, A., Garcia, F., Lei, L., Gass, D. A., Amendolara, B., Bruce, J. N., Canoll, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0084-14.2014 · Cited by 116
Abedalthagafi, M., Phillips, J. J., Kim, G., Mueller, S., Haas-Kogen, D. A., Marshall, R. E., Croul, S. E., Santi, M., Cheng, J. Q., Zhou, S., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.90 · Cited by 118
Erson-Omay, Z., Çağlayan, A. O., Schultz, N. D., Weinhold, N., Omay, S. B., Özduman, K., Köksal, Y., Li, J., Harmancı, A. S., Clark, V. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov027 · Cited by 116
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 124
Tamura, R., Tanaka, T., Miyake, K., Yoshida, K., & Sasaki, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0284-x · Cited by 116
Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies
Caffery, B., Lee, J. S., & Alexander-Bryant, A. A. (2019) · Nanomaterials · doi:10.3390/nano9010105 · Cited by 121
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy
Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701291 · Cited by 130
Kong, J., Cooper, L., Wang, F., Gao, J., Teodoro, G., Scarpace, L. M., Mikkelsen, T., Schniederjan, M., Moreno, C. S., Saltz, J. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081049 · Cited by 115
Feng, H., Hu, B., Liu, K.-W., Li, Y., Lu, X., Cheng, T., Yiin, J., Lu, S., Keezer, S. M., Fenton, T. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58559 · Cited by 117
Self-citationRetractedJohnson, K. C., Houseman, E. A., King, J. E., von Herrmann, K. M., Fadul, C. E., & Christensen, B. C. (2016) · Nature Communications · doi:10.1038/ncomms13177 · Cited by 123
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Hu, X., Martínez-Ledesma, E., Zheng, S., Kim, H., Barthel, F. P., Jiang, T., Hess, K. R., & Verhaak, R. G. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now285 · Cited by 114
Self-citationApoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications
Valdés-Rives, S. A., Casique‐Aguirre, D., German‐Castelan, L., Velasco-Velázquez, M. A., & González‐Arenas, A. (2017) · BioMed Research International · doi:10.1155/2017/7403747 · Cited by 117
Chandran, V. I., Welinder, C., Månsson, A., Offer, S., Freyhult, E., Pernemalm, M., Lund, S. M., Pedersen, S., Lehtiö, J., Marko‐Varga, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2946 · Cited by 117
Redefining the IBDs using genome-scale molecular phenotyping
Furey, T. S., Sethupathy, P., & Sheikh, S. Z. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0118-x · Cited by 120
Marques, C., Unterkircher, T., Kroon, P., Oldrini, B., Izzo, A., Dramaretska, Y., Ferrarese, R., Kling, E., Schnell, O., Nelander, S., et al. (2021) · eLife · doi:10.7554/elife.64846 · Cited by 117
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
